Sustiva / Efavirenz
Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
This single-ingredient finding does not establish dosing for combination tablets or dialysis.
Before applying: Verify the current prescribing information for this presentation.
Also check: Sustiva - product and source limitations
Adults: 600 mg orally daily, fasting, preferably at bedtime; renal dose modification is not required.
Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.
Retrieved: 2026-11-07
Source revision: DailyMed SPL version 2, posted Mar 01, 2013
Renal measure: Renal impairment categories as defined by the cited product label
Read this dated source findingRetrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.
Renal measure: Use the renal measure explicitly present in the RX passage.
Read this dated source findingChoose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Read 1 source difference / applicability notes
Preserved historical content; not revalidated as current prescribing guidance.
Efavirenz (Sustiva), oral tablet
Efavirenz (Sustiva), oral tablet
Adults with HIV; product-specific renal recommendations.
These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Open / share selected sourcesThese protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
This single-ingredient finding does not establish dosing for combination tablets or dialysis.
How to use this: Verify the current prescribing information for this presentation.
Efavirenz (Sustiva), oral tablet
Efavirenz (Sustiva), oral tablet
Adults with HIV; product-specific renal recommendations.
Preserved source. Not revalidated as current labeling.
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
The interacting-drug recommendations are preserved from the historical page and require comparison with current HIV guidance.
Adults: SUSTIVA 600 mg orally once daily with a protease inhibitor and/or NRTIs. Take on an empty stomach, preferably at bedtime. Food increases concentrations and may increase adverse reactions; bedtime dosing can improve nervous-system tolerability. Always combine with other antiretrovirals.
With voriconazole: increase voriconazole maintenance to 400 mg every 12 hours and decrease efavirenz to 300 mg daily using capsules (one 200 mg plus two 50 mg, or six 50 mg capsules). Do not break SUSTIVA tablets.
With rifampin in patients >=50 kg, the source recommends increasing efavirenz to 800 mg daily.
No adjustments needed.
Insufficient data.
Open / share this exact local source
Renal pharmacokinetic studies are lacking. The small fraction of efavirenz eliminated unchanged in urine suggests little direct renal effect on elimination. This single-ingredient finding does not establish dosing for combination tablets or dialysis.
RDM74-sustiva-official-1 · Source locator: Renal guidance: Special Populations
Open / share this exact local source
Renal pharmacokinetic studies are lacking. The small fraction of efavirenz eliminated unchanged in urine suggests little direct renal effect on elimination.
RDM74-sustiva-rxlist-1 · Source locator: RX List: selected renal passage
This mirror and the underlying product label share a source family.
Open / share this exact local source
Adults: 600 mg orally daily, fasting, preferably at bedtime; renal dose modification is not required.
efavirenz:nih-arv-efavirenz-1 · Source locator: Appendix B: Efavirenz row
The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.
Read the full coverage report